Alpha Cognition

ACOG · NASDAQ

$8.61+$0.11 (+1.29%)TodayMarket closed · Oct 20, 4:10 PM ET

Prev close $8.50

Latest news

Press releaseOct 13, 8:30 AM ETBusiness Wire
Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®
Press releaseOct 6, 8:30 AM ETBusiness Wire
Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
Press releaseOct 2, 7:06 PM ETBusiness Wire
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseOct 1, 8:30 AM ETBusiness Wire
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
Press releaseSep 9, 6:00 PM ETBusiness Wire
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseSep 1, 5:00 PM ETBusiness Wire
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsAug 13, 5:20 PM ET
Alpha Cognition Q2 2026 Earnings Call Transcript
Press releaseAug 13, 4:05 PM ETBusiness Wire
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
Press releaseAug 3, 8:30 AM ETBusiness Wire
Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update
Press releaseJul 29, 8:30 AM ETBusiness Wire
Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease
Press releaseJul 10, 8:30 AM ETBusiness Wire
Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
Press releaseJun 23, 8:30 AM ETBusiness Wire
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Press releaseJun 16, 8:30 AM ETBusiness Wire
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease
Press releaseJun 9, 8:00 AM ETBusiness Wire
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's Disease
NewsMay 29, 5:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsMay 28, 8:06 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsMay 14, 5:10 PM ET
Full Transcript: Alpha Cognition Q1 2026 Earnings Call
NewsMay 14, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseMay 14, 4:15 PM ETBusiness Wire
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
NewsMay 14, 7:11 AM ET
Earnings Scheduled For May 14, 2026
Press releaseApr 28, 4:30 PM ETBusiness Wire
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
Press releaseApr 27, 8:00 AM ETBusiness Wire
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
Press releaseApr 20, 5:00 PM ETBusiness Wire
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
Press releaseApr 15, 8:00 PM ETBusiness Wire
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseApr 1, 4:30 PM ETBusiness Wire
Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury
NewsMar 26, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseMar 26, 4:01 PM ETBusiness Wire
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
NewsMar 26, 7:11 AM ET
Earnings Scheduled For March 26, 2026
NewsMar 19, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseMar 13, 1:46 PM ETBusiness Wire
Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026
Press releaseMar 10, 8:30 AM ETBusiness Wire
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences
Press releaseFeb 25, 8:30 AM ETBusiness Wire
Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
Press releaseFeb 18, 8:30 AM ETBusiness Wire
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens
Press releaseJan 7, 4:30 PM ETBusiness Wire
Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution
NewsApr 24, 5:30 AM ETAvi Kapoor
Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®

Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Q2 2026 Earnings Call Transcript

Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update

Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease

Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's Disease

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Full Transcript: Alpha Cognition Q1 2026 Earnings Call

12 Health Care Stocks Moving In Thursday's After-Market Session

Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

Earnings Scheduled For May 14, 2026

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

12 Health Care Stocks Moving In Thursday's After-Market Session

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Earnings Scheduled For March 26, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution

Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket